← Browse by Condition
Medical Condition

solid tumor

Total Trials
37
Recruiting Now
37
Trial Phases
Phase 1, Phase 2, Phase 2, EARLY_Phase 1

ClinicalMetric tracks all active clinical trials for solid tumor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — solid tumor Clinical Trials

How many clinical trials are currently recruiting for solid tumor?
ClinicalMetric currently tracks 37 actively recruiting clinical trials for solid tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 37. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for solid tumor?
solid tumor research spans Phase 1 (28 trials), Phase 2 (13 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a solid tumor clinical trial?
Eligibility criteria for solid tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
28
Phase 2
13
Top Sponsors
Sichuan Baili Pharmaceutical Co., Ltd. 2 trials
Bliss Biopharmaceutical (Hangzhou) Co., Ltd 2 trials
Parabilis Medicines, Inc. 1 trial
Psivac Ltd 1 trial
Innovent Biologics Technology Limited (Shanghai R&D Center) 1 trial

Recruiting Clinical Trials

NCT05919264 Phase 1, Phase 2
Recruiting
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Enrollment
619 pts
Location
United States, Austr...
Sponsor
Parabilis Medicines, Inc.
View Trial →
NCT05785039 Phase 2
Recruiting
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Enrollment
76 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
View Trial →
NCT06549946 Phase 1, Phase 2
Recruiting
Ixovex-1 Single Agent and Combination Therapy
Enrollment
18 pts
Location
United Kingdom
Sponsor
Psivac Ltd
View Trial →
NCT07327632 EARLY_Phase 1
Recruiting
This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
Enrollment
300 pts
Location
China
Sponsor
Innovent Biologics Technology ...
View Trial →
NCT07556276 Phase 1, Phase 2
Recruiting
Study of CMTS1215 Injection in Patients With Solid Tumors
Enrollment
20 pts
Location
China
Sponsor
The Second Hospital of Nanjing...
View Trial →
NCT06646952
Recruiting
CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Enrollment
30 pts
Location
China
Sponsor
Hua Zhu
View Trial →
NCT06425926 Phase 1, Phase 2
Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Enrollment
117 pts
Location
United States
Sponsor
Georgiamune Inc
View Trial →
NCT06440005 Phase 1
Recruiting
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Enrollment
80 pts
Location
United States
Sponsor
Angiex, Inc.
View Trial →
NCT04300556 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Enrollment
182 pts
Location
United States, Franc...
Sponsor
Eisai Inc.
View Trial →
NCT06010342 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
Enrollment
60 pts
Location
United States, China
Sponsor
Teligene US
View Trial →
NCT06531486 Phase 1
Recruiting
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
Enrollment
96 pts
Location
China
Sponsor
Shanghai Fosun Pharmaceutical ...
View Trial →
NCT05382559 Phase 1
Recruiting
A Study of ASP3082 in Adults With Advanced Solid Tumors
Enrollment
681 pts
Location
United States, China...
Sponsor
Astellas Pharma Inc
View Trial →
NCT05868226 Phase 1, Phase 2
Recruiting
PRE-ISPY Phase I/II Oncology Platform Program
Enrollment
280 pts
Location
United States
Sponsor
QuantumLeap Healthcare Collabo...
View Trial →
NCT07753226 Phase 1
Recruiting
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Enrollment
39 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
View Trial →
NCT07715747 Phase 1
Recruiting
A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors
Enrollment
128 pts
Location
China
Sponsor
TJ Biopharma Co., Ltd.
View Trial →
NCT07703163 Phase 1
Recruiting
Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer
Enrollment
15 pts
Location
China
Sponsor
West China Hospital
View Trial →
NCT05907980 Phase 1
Recruiting
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Enrollment
209 pts
Location
United States, Japan
Sponsor
Chugai Pharmaceutical
View Trial →
NCT05786924 Phase 1, Phase 2
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Enrollment
554 pts
Location
United States, Austr...
Sponsor
Institut de Recherches Interna...
View Trial →
NCT06248697 EARLY_Phase 1
Recruiting
Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors
Enrollment
16 pts
Location
China
Sponsor
Shanghai Cell Therapy Group Co...
View Trial →
NCT06166888 Phase 1
Recruiting
A Study of AK131 in Patients With Advanced Solid Tumors
Enrollment
130 pts
Location
China
Sponsor
Akeso
View Trial →
NCT07541573 Phase 1
Recruiting
GTB-5550 in Advanced Solid Tumors
Enrollment
175 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
View Trial →
NCT02332668 Phase 1, Phase 2
Recruiting
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Enrollment
370 pts
Location
United States, Brazi...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT05522868 Phase 1
Recruiting
SB17170 Phase 1 Clinical Trial in Solid Tumors
Enrollment
50 pts
Location
South Korea
Sponsor
SPARK Biopharma
View Trial →
NCT06578624 Phase 1, Phase 2
Recruiting
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment
55 pts
Location
United States
Sponsor
Lamassu Bio Inc
View Trial →
NCT05217693 Phase 1
Recruiting
A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
Enrollment
288 pts
Location
China
Sponsor
Bliss Biopharmaceutical (Hangz...
View Trial →
NCT06375187 Phase 1
Recruiting
A Study of GC203 TIL in Advanced Malignant Solid Tumors
Enrollment
18 pts
Location
China
Sponsor
Shanghai Juncell Therapeutics
View Trial →
NCT04243720
Recruiting
Immune Resistance Interrogation Study
Enrollment
100 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →
NCT05269316 Phase 1, Phase 2
Recruiting
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Enrollment
61 pts
Location
United States, Austr...
Sponsor
Impact Therapeutics, Inc.
View Trial →
NCT06942104 Phase 1
Recruiting
Imaging of Solid Tumors Using 18F-TRX
Enrollment
56 pts
Location
United States
Sponsor
Rahul Aggarwal
View Trial →
NCT00736749
Recruiting
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Enrollment
25,000 pts
Location
United States, Puert...
Sponsor
Children's Oncology Group
View Trial →
NCT06739395 Phase 2
Recruiting
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Enrollment
300 pts
Location
China
Sponsor
Tianjin Medical University Sec...
View Trial →
NCT06132828 Phase 1
Recruiting
Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors
Enrollment
216 pts
Location
China
Sponsor
Zhejiang Doer Biologics Co., L...
View Trial →
NCT07419581
Recruiting
A Study of Freeze-Dried Miracle Fruit (MiraBurst) on Participants Receiving Cancer Treatment
Enrollment
45 pts
Location
United States
Sponsor
Case Comprehensive Cancer Cent...
View Trial →
NCT06241898 Phase 1
Recruiting
A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors
Enrollment
300 pts
Location
China
Sponsor
Bliss Biopharmaceutical (Hangz...
View Trial →
NCT06644300 Phase 1
Recruiting
Study of BM230 in Patients With Advanced Solid Tumors
Enrollment
123 pts
Location
Australia, China
Sponsor
Suzhou Biomissile Pharmaceutic...
View Trial →
NCT06102837
Recruiting
Tumor Vaccines for Solid Tumors
Enrollment
340 pts
Location
China
Sponsor
Huashan Hospital
View Trial →
NCT06536257
Recruiting
Personalised Immunotherapy Platform
Enrollment
1,000 pts
Location
Australia
Sponsor
Melanoma Institute Australia
View Trial →

Related Conditions

breast cancer (4) cancer (3) colorectal cancer (3) metastatic cancer (3) solid carcinoma (3) prostate cancer (2) advanced solid tumor (2) melanoma (2) locally advanced solid tumor (1) wnt pathway (1) hcc (1) desmoid (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology